Navigation Links
Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors

Company Mails Letter to Shareholders

MONTVALE, N.J., Dec. 12 /PRNewswire-FirstCall/ -- Datascope Corp. (Nasdaq: DSCP) today announced that Glass Lewis & Co., one of the nation's leading independent proxy advisory firms, recommends that Datascope shareholders re-elect the Board's nominees -- James J. Loughlin and William L. Asmundson -- at the Company's Annual Meeting of Shareholders on Thursday, December 20, 2007. To follow Glass Lewis' recommendation, Datascope shareholders should vote FOR the re-election of the Company's nominees on the BLUE proxy card today.

In its December 10, 2007 report, Glass Lewis stated*:

-- " ... we do not believe that shareholders would be best served by

replacing directors [William] Asmundson and [James] Loughlin with the

Ramius Group's nominees."

-- " ... we do not believe that replacing directors Asmundson and Loughlin

with Dr. Dantzker and Mr. Fox would be the appropriate vehicle at this

time to serve shareholders' best interests."

-- " ... we also recognize that that [Mr. Asmundson's] seasoned experience

on this board could be a positive factor for shareholders."

-- " ... we maintain that shareholders should support the management

nominees ... "

Datascope also today sent the following letter to all shareholders from Robert E. Klatell, Chairman of the Company's Nominations and Corporate Governance Committee.

The full text of Datascope's letter follows:

December 12, 2007



Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends A Vote FOR

The Company's Nominees, James J. Loughlin And William L. Asmundson.

Dear Shareholder:

With Datascope's December 20th Annual Meeting of Shareholders rapidly approaching, your Board of Directors unanimously recommends that shareholders re-elect Datascope's directors, James J. Loughlin and William L. Asmundson, by voting "FOR" on the enclosed BLUE proxy card today.

For your convenience, telephone and Internet voting is available. Simply follow the instructions on the enclosed proxy card. Alternatively, you can vote by mail by signing, dating and returning the BLUE proxy card in the enclosed pre-addressed, stamped envelope.


Your Board strongly urges all shareholders to re-elect James Loughlin and William Asmundson -- and here's why:

-- William Asmundson is a successful investment manager. In his career,

he has served as CEO and Chief Investment Officer of Rockefeller & Co.

and related investment companies during a 17-year tenure. Bill is

currently a General Partner of a global investment fund. Bill brings

exceptional experience and the perspective of institutional investors

to the Board. Bill serves as the lead outside director of Datascope's

Board and presides over executive sessions and meetings of the outside

directors, coordinates the activities of the outside directors and acts

as an intermediary between the Board and management.

-- James Loughlin brings exceptional experience to Datascope through his

more than 40 years of accomplishments at KPMG, one of the world's major

accounting firms. Jim chaired KPMG's Life Science and Pharmaceuticals

practices and, for seven years, led its representation of the world's

largest pharmaceutical company. Jim is a financial expert under SEC

rules, serves as Chairman of the Audit Committee and as a member of the

Compensation Committee. Jim first joined Datascope's Board in 2004.

Datascope has recruited and continues to recruit directors with a blend of business talents, skill sets and experience to further strengthen the Board and add fresh perspectives. Over the past four years, the Board has recruited Rob Klatell, Jim Loughlin and William Wyman. Bill Wyman has extensive experience in the medical industry from his role as a trustee of the Mary Hitchcock Memorial Hospital, a 400-bed primary trauma center, for 12 years; a trustee of The Dartmouth Clinic, a 650 doctor entity, for six years; and a trustee of the Dartmouth Hitchcock Medical Center (the largest academic medical center in northern New England), which oversees and coordinates the operations of the Mary Hitchcock Memorial Hospital, The Dartmouth Clinic, the Dartmouth Medical School and a local VA hospital, for four years.

THEY OFFER SHAREHOLDERS NOTHING As you consider your vote for the upcoming Annual Meeting, keep in mind the following four things about Ramius and its candidates:

-- Ramius is a short-sighted hedge fund that did not own a single share in

Datascope until three months ago.

-- Ramius and its nominees have NO PLAN for Datascope or its shareholders.

-- Ramius' nominees, if elected, would serve NO BUSINESS PURPOSE on your

Board other than to advance Ramius' short-term, opportunistic


-- Ramius' nominees, if elected, could jeopardize Datascope's strategic

direction and negatively affect the value of your investment.

The Ramius nominees are not qualified to be elected to your Board. They have neither the skill set, the experience nor the independence to add anything constructive to your Board. Ramius seeks your support, but offers you nothing in return.


Your Board stands firmly behind Datascope's management team and strategy. We are extremely excited about our new products, R&D pipeline, and the operating changes being implemented by our senior management team. At the same time, your Board remains committed to returning excess capital to shareholders. Your Board recommends that all shareholders support this team by voting FOR James Loughlin and William Asmundson on the BLUE proxy card today.

Datascope is moving forward vigorously with its plans to increase shareholder value and drive sustainable and profitable growth. Key elements of Datascope's strategic plan include:

-- Strengthening our senior management team. In October 2007, Datascope

promoted Dr. Antonino Laudani to the newly-established role of Chief

Operating Officer.

-- Continued expansion of our innovative product portfolio. In early

October 2007, Datascope launched NetGuard(TM), our revolutionary new

Clinical Alert System. Datascope conservatively estimates the market

potential for NetGuard to be in excess of $1 billion in annual sales in

the U.S. alone.

-- In addition to introducing nine new patient monitoring products in

2007, our new Sensation(TM) 7 Fr. fiber-optic balloon catheter and the

CS300 intra aortic balloon pump (IABP) underscore Datascope's

leadership position in the Cardiac Assist market.

-- Continued investment in Research & Development. Investment in R&D is

critical to Datascope's continued growth and success. We are committed

to continuing to invest in R&D and have a number of exciting new

products in the pipeline.

-- Focusing on growing our core businesses. In October 2006, after

thorough analysis, your Board and senior management determined to exit

the interventional products market. We also established Datascope

Japan K.K. as a wholly-owned subsidiary to manage our IABP business in

Japan, the world's second largest market for medical devices.

-- Making strategic acquisitions and other investments. In June 2007,

Datascope acquired Artema Medical AB, its most recent acquisition,

continuing our expansion of product offerings in the anesthesia

monitoring market.



Your vote is important, no matter how many shares you own. Please vote by Internet or phone by following the simple instructions on your BLUE proxy card or vote by mail by signing, dating and returning the BLUE proxy card in the enclosed pre-addressed, stamped envelope.

Do NOT vote the Ramius WHITE card. Please simply ignore or throw away any of the Ramius cards you may receive. To be sure we have your proxy in time to be counted, please take a minute NOW to vote your shares.

We thank you for your continued support. If you have any questions or need any assistance voting your shares, please contact MacKenzie Partners, Inc. which is assisting the Company in this matter, toll-free at (800) 322- 2885 or


On behalf of The Board of Directors of Datascope,

/s/ Robert E. Klatell

Robert E. Klatell

Chairman of Datascope's Nominations and Corporate Governance Committee

The Company urges all its stockholders to re-elect its directors at the upcoming Annual Meeting of Shareholders currently scheduled for Thursday, December 20, 2007 by voting promptly on the BLUE proxy by telephone, Internet or mail. If shareholders have any questions or need assistance in voting they should contact MacKenzie Partners, Inc. at 800-322-2885 or by email at

* Permission to use quotations was neither sought nor obtained.

About Datascope Corp.

Datascope Corp. is the global leader of intra-aortic balloon counterpulsation and a diversified medical device company that develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology and radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical care. The Company's products are sold throughout the world through direct sales representatives and independent distributors. Founded in 1964, Datascope is headquartered in Montvale, New Jersey. For news releases, webcasts and other Company information please visit Datascope's website,

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements that address expectations or projections about the future, including statements about Datascope's strategy for growth, product development, market and growth opportunities, and future performance are forward-looking statements. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Important factors that could cause actual results to differ materially from our expectations are disclosed in our filings with the United States Securities and Exchange Commission ("SEC"). These factors include, but are not limited to, the risk that NetGuard does not have the potential to create a new, significant market in monitoring currently unmonitored patients, that Datascope is not the first company to address this market, that NetGuard and other new products offered or anticipated to be offered by Datascope will not be a significant opportunity for new growth or may not be accepted in the marketplace, and that market conditions may change, particularly as the result of competitive activity in the markets served by Datascope. Datascope's filings with the SEC can be obtained at no charge at, as well as through our website at

This solicitation is being made by the Board of Directors of Datascope Corp. Information regarding the Board as participants in the solicitation is contained in the Definitive Proxy Statement of Datascope Corp. on file with the SEC. Such proxy statement may be obtained without charge from the SEC's website at and has been distributed to shareholders on or about November 5, 2007. We urge you to read the proxy statement in full because it contains important information. Requests for copies should be directed to Datascope Corp.'s proxy solicitor, MacKenzie Partners, Inc. at 800-322-2885 or


Matthew Sherman / Michael Cuneo

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449

Larry Dennedy / Joseph Doherty

MacKenzie Partners, Inc.

(212) 929-5500

SOURCE Datascope Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Fluorescent glass SRMs are new tool for spectroscopy
2. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
3. Report recommends off-site disposal of secondary waste
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. Report recommends off-site disposal of secondary waste
6. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
9. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
10. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
11. Pharmos Issues Letter to Shareholders
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):